H. Ascher-svanum, B. Zhu, D. E. Faries, D. Salkever, E. P. Slade et al., The cost of relapse and the predictors of relapse in the treatment of schizophrenia, BMC Psychiatry, vol.10, issue.2, 2011.

D. Robinson, M. G. Woerner, J. M. Alvir, R. Bilder, R. Goldman et al., Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder, Arch Gen Psychiatry, vol.56, pp.241-247, 1999.

D. Wiersma, F. J. Nienhuis, C. J. Slooff, and R. Giel, Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort, Schizophr Bull, vol.24, pp.75-85, 1998.

A. G. Awad and L. N. Voruganti, The burden of schizophrenia on caregivers: a review, Pharmacoeconomics, vol.26, pp.149-162, 2008.

S. Almond, M. Knapp, C. Francois, M. Toumi, and T. Brugha, Relapse in schizophrenia: costs, clinical outcomes and quality of life, Br J Psychiatry, vol.184, pp.346-351, 2004.

J. Hong, F. Windmeijer, D. Novick, J. M. Haro, and J. Brown, The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study, Prog Neuropsychopharmacol Biol Psychiatry, vol.33, pp.835-841, 2009.

T. P. Gilmer, C. R. Dolder, J. P. Lacro, D. P. Folsom, L. Lindamer et al., Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia, Am J Psychiatry, vol.161, pp.692-699, 2004.

J. L. Ayuso-gutierrez, D. R. Vega, and J. M. , Factors influencing relapse in the long-term course of schizophrenia, Schizophr Res, vol.28, pp.199-206, 1997.

I. Lipkovich, W. Deberdt, J. G. Csernansky, P. Buckley, J. Peuskens et al., Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy, J Psychiatr Res, vol.41, pp.305-310, 2007.

J. Van-os, S. Kapur, and . Schizophrenia, Lancet, vol.374, pp.635-645, 2009.

J. Allardyce and J. Boydell, Review: the wider social environment and schizophrenia, Schizophr Bull, vol.32, pp.592-598, 2006.

M. Power, A. Harper, and M. Bullinger, The World Health Organization WHOQOL-100: tests of the universality of Quality of Life in 15 different cultural groups worldwide, Health Psychol, vol.18, pp.495-505, 1999.

K. Kalantar-zadeh, J. D. Kopple, G. Block, and M. H. Humphreys, Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis, J Am Soc Nephrol, vol.12, pp.2797-2806, 2001.

M. B. Parshall, D. W. Mapel, L. Rice, A. Williams, and J. O'reilly, Predictive validity of short-form health survey [36 items] scales for chronic obstructive pulmonary disease exacerbation, Heart Lung, vol.37, pp.356-365, 2008.

S. Sehlen, M. Lenk, H. Hollenhorst, B. Schymura, U. Aydemir et al., Quality of life (QoL) as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy, Onkologie, vol.26, pp.38-43, 2003.

M. D. Sprenkle, D. E. Niewoehner, D. B. Nelson, and K. L. Nichol, The Veterans Short Form 36 questionnaire is predictive of mortality and health-care utilization in a population of veterans with a self-reported diagnosis of asthma or COPD, Chest, vol.126, pp.81-89, 2004.

W. Yeo, F. K. Mo, J. Koh, A. T. Chan, T. Leung et al., Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma, Ann Oncol, vol.17, pp.1083-1089, 2006.

E. Y. Chen, C. L. Hui, E. L. Dunn, M. Y. Miao, W. S. Yeung et al., A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients, Schizophr Res, vol.77, pp.99-104, 2005.

P. J. Weiden and M. Olfson, Cost of relapse in schizophrenia, Schizophr Bull, vol.21, pp.419-429, 1995.

P. E. Bebbington, M. Angermeyer, J. M. Azorin, T. Brugha, R. Kilian et al., The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study, Soc Psychiatry Psychiatr Epidemiol, vol.40, pp.707-717, 2005.

, Diagnostic and Statistical Manual of Mental Disorders, 1994.

S. R. Kay, L. A. Opler, and A. Fiszbein, Significance of positive and negative syndromes in chronic schizophrenia, Br J Psychiatry, vol.149, pp.439-448, 1986.

J. Endicott, R. L. Spitzer, J. L. Fleiss, and J. Cohen, The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance, Arch Gen Psychiatry, vol.33, pp.766-771, 1976.

S. Simpson and R. Angus, A rating scale for extrapyramidal side effects, Acta Psychiatr Scand Suppl, issue.212, pp.11-19, 1970.

T. R. Barnes, A rating scale for drug-induced akathisia, Br J Psychiatry, vol.154, pp.672-676, 1989.

R. D. Lane, W. M. Glazer, T. E. Hansen, W. H. Berman, and S. I. Kramer, Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale, J Nerv Ment Dis, vol.173, pp.353-357, 1985.

P. Weiden, B. Rapkin, T. Mott, A. Zygmunt, D. Goldman et al., Rating of medication influences (ROMI) scale in schizophrenia, Schizophr Bull, vol.20, pp.297-310, 1994.

J. E. Ware and C. D. Sherbourne, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, vol.30, pp.473-483, 1992.

A. F. Lehman, A quality of life interview for the chronically mentally ill, Eval Program Plann, vol.11, issue.1, pp.51-62, 1988.

M. Lader, What is relapse in schizophrenia?, Int Clin Psychopharmacol, vol.9, issue.5, pp.5-9, 1995.

S. Leucht, T. R. Barnes, W. Kissling, R. R. Engel, C. Correll et al., Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials, Am J Psychiatry, vol.160, pp.1209-1222, 2003.

J. A. Cramer, R. Rosenheck, W. Xu, J. Thomas, W. Henderson et al., Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia, Schizophr Bull, vol.26, pp.659-666, 2000.

G. Reine, M. C. Simeoni, P. Auquier, A. Loundou, V. Aghababian et al., Assessing health-related quality of life in patients suffering from schizophrenia: a comparison of instruments, Eur Psychiatry, vol.20, pp.510-519, 2005.

D. Hert, M. Cohen, D. Bobes, J. Cetkovich-bakmas, M. Leucht et al., Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level, World Psychiatry, vol.10, pp.138-151, 2011.

H. Millar, Management of physical health in schizophrenia: a stepping stone to treatment success, Eur Neuropsychopharmacol, vol.18, issue.2, pp.121-128, 2008.

G. Chabungbam, A. Avasthi, and P. Sharan, Sociodemographic and clinical factors associated with relapse in schizophrenia, Psychiatry Clin Neurosci, vol.61, pp.587-593, 2007.

D. Roe, M. Mashiach-eizenberg, and P. H. Lysaker, The relation between objective and subjective domains of recovery among persons with schizophreniarelated disorders, Schizophr Res, vol.131, pp.133-138, 2011.

S. M. Silverstein and A. S. Bellack, A scientific agenda for the concept of recovery as it applies to schizophrenia, Clin Psychol Rev, vol.28, pp.1108-1124, 2008.

L. Boyer, R. Richieri, C. Faget, R. Padovani, F. Vaillant et al., Functional involvement of superior temporal sulcus in quality of life of patients with schizophrenia, Psychiatry Res, vol.202, issue.2, pp.155-160, 2012.

P. H. Lysaker, M. A. Erickson, B. Buck, K. D. Buck, K. Olesek et al., Metacognition and social function in schizophrenia: associations over a period of five months, Cogn Neuropsychiatry, vol.16, pp.241-255, 2011.

P. H. Lysaker, K. D. Buck, A. Carcione, M. Procacci, G. Salvatore et al., Addressing metacognitive capacity for self reflection in the psychotherapy for schizophrenia: a conceptual model of the key tasks and processes, Psychol Psychother, 2010.

I. R. Falloon, Relapse: a reappraisal of assessment of outcome in schizophrenia, Schizophr Bull, vol.10, pp.293-299, 1984.

O. Caseiro, R. Pérez-iglesias, I. Mata, O. Martínez-garcia, J. M. Pelayo-terán et al., Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study, J Psychiatr Res, vol.2012, issue.8, pp.1099-1105

W. W. Fleischhacker, J. Rabinowitz, G. Kemmler, M. Eerdekens, and A. Mehnert, Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year, Br J Psychiatry, vol.187, pp.131-136, 2005.

D. Papaioannou, J. Brazier, and G. Parry, How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review, Value Health, vol.14, pp.907-920, 2011.

D. I. Velligan, P. J. Weiden, M. Sajatovic, J. Scott, D. Carpenter et al., The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness, J Clin Psychiatry, vol.70, issue.4, pp.47-48, 2009.

A. G. Awad and L. N. Voruganti, Intervention research in psychosis: issues related to the assessment of quality of life, Schizophr Bull, vol.26, pp.557-564, 2000.

S. M. Gilbody, A. O. House, and T. A. Sheldon, Psychiatrists in the UK do not use outcomes measures. National survey, Br J Psychiatry, vol.180, pp.101-103, 2002.

J. Greenhalgh, A. F. Long, and R. Flynn, The use of patient reported outcome measures in routine clinical practice: lack of impact or lack of theory?, Soc Sci Med, vol.60, pp.833-843, 2005.

L. Boyer and P. Auquier, The lack of impact of quality-of-life measures in schizophrenia: a shared responsibility, Pharmacoeconomics, vol.2012, issue.6, pp.531-533

. Boyer, Quality of life is predictive of relapse in schizophrenia, BMC Psychiatry, vol.13, p.15, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-02651161